BMEA logo

BMEA
Biomea Fusion Inc

2,316
Mkt Cap
$97.6M
Volume
1.91M
52W High
$3.08
52W Low
$0.8719
PE Ratio
-1.51
BMEA Fundamentals
Price
$1.35
Prev Close
$1.43
Open
$1.42
50D MA
$1.55
Beta
1.57
Avg. Volume
1.97M
EPS (Annual)
-$1.18
P/B
5.21
Rev/Employee
$0.00
$10.54
Loading...
Loading...
News
all
press releases
Biomea Fusion Status Update: Experts Discuss Icovamenib's Promise Ahead of ADA 2026
Rodman & Renshaw Director of Research Michael King hosted an endocrinology-focused discussion with Dr. Alexander Abitbol, an endocrinologist and assistant medical director at LMC Healthcare, ahead of the American Diabetes Association (ADA) meeting in New Orleans. The conversation centered on tre...
MarketBeat·11d ago
News Placeholder
More News
News Placeholder
Biomea Fusion (NASDAQ:BMEA) Coverage Initiated by Analysts at Citizens Jmp
Citizens Jmp began coverage on shares of Biomea Fusion in a research note on Tuesday. They issued a 'market outperform' rating and a $9.00 target price on the stock...
MarketBeat·11d ago
News Placeholder
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of "Moderate Buy" from Analysts
Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings...
MarketBeat·16d ago
News Placeholder
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib
Biomea Fusion (NASDAQ:BMEA) executives highlighted early, exploratory clinical data for icovamenib in type 1 diabetes, presenting top-line results from the company's COVALENT-112 proof-of-concept...
MarketBeat·18d ago
News Placeholder
Biomea Fusion (NASDAQ:BMEA) Given Buy Rating at D. Boral Capital
D. Boral Capital reissued a "buy" rating and issued a $12.00 price objective on shares of Biomea Fusion in a research report on Tuesday...
MarketBeat·18d ago
News Placeholder
Biomea Fusion (BMEA) Expected to Announce Quarterly Earnings on Monday
Biomea Fusion (NASDAQ:BMEA) will be releasing its Q1 2026 earnings before the market opens on Monday, May 4. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-4-biomea-fusion-inc-stock...
MarketBeat·19d ago
News Placeholder
Biomea Fusion (NASDAQ:BMEA) Receives Buy Rating from D. Boral Capital
D. Boral Capital restated a "buy" rating and issued a $12.00 price objective on shares of Biomea Fusion in a research note on Wednesday...
MarketBeat·1mo ago
News Placeholder
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Biomea Fusion, Inc. (NASDAQ:BMEA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the nine ratings firms that are covering the company, Marketbeat reports. One investment...
MarketBeat·1mo ago
News Placeholder
Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts
Executives from Biomea Fusion (NASDAQ:BMEA) discussed the company's lead diabetes program, icovamenib, and outlined near-term clinical milestones during a recent company event hosted by an operator...
MarketBeat·2mo ago
News Placeholder
Biomea Fusion Teases Q2 Phase 1 Data for Oral GLP-1 BMF-650, Advances Icovamenib in Diabetes
Biomea Fusion (NASDAQ:BMEA) outlined several near-term clinical milestones and development priorities during a JPMorgan conference call, with executives emphasizing upcoming Phase I data for its oral GLP-1 receptor agonist candidate BMF-650 and continued advancement of icovamenib in diabetes. BMF-6...
MarketBeat·2mo ago
<
1
2
...
>

Latest BMEA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.